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Introduction
The metabolic requirements of cancer cells are different than those of normal tissues [1, 2] . For example, the liver kinase B1 (LKB1) tumor suppressor protein is dysfunctional in approximately 30% of non-small cell lung carcinomas (NSCLCs) and plays a critical role in the cellular response to energy stress [3] . Defects in such metabolic regulation may serve as potential points for therapeutic intervention. To exploit this phenomenon we must identify the most highly activated metabolic fluxes in cancer cells as a function of their genetic background (e.g. functional status of the LKB1-deficient tumor suppressor) and stress level. Systems-based approaches are required to quantitatively describe these interconnected pathways in sufficient detail to determine optimal enzyme targets under conditions of stress [4] . We hypothesize that combining these compounds with inhibitors of glutamine metabolism will be an effective therapy for LKB1-deficient lung tumors. The objective of this research is to identify metabolic susceptibilities in LKB1-deficient NSCLC using systems-level metabolic flux analysis. Subsequent studies in Year 2 of this grant will aim to design combinatorial treatments that simultaneously induce these dependencies and target compensatory pathways.
Body
A description of specific results associated with each Task scheduled for Year 1 is included below. Tasks with work completed or in progress are in black and those tasks scheduled for completion in Year 2 are in gray font. Task 1. Perform systems-level metabolic analysis of isogenic NSCLC cell lines expressing or lacking functional LKB1 using isotope tracers. Lines to be studied include vector control (LKB1-deficient), wild-type (WT) LKB1, and kinase dead (KD) LKB1-expressing A549 cells. Work to be performed by Hui Zhang and graduate student to be named (Seth Parker) (months 1-6) 1a. Generate 13 C-labeling data in the above cell lines using glucose and glutamine tracers under conditions of nutrient withdrawal and hypoxia (months 1-4). 1b. Measure nutrient uptake and byproduct secretion rates under the above conditions (months 1-4). 1c. Validate signaling downstream of LKB under the above conditions (months 1-4). 1d. Perform computational analyses of these data to generate comprehensive flux maps of NSCLC cells +/-LKB1 (months 3-6).
We have completed extensive studies comparing A549 cells engineered with an empty pBABE control vector (vec.) versus those expressing function (wild-type) LKB1 protein (+LKB1). These results are presented in Figure 1 reaction arrow colored red) was increased when functional LKB1 was present in NSCLC cells. Consistent with this expected change, we observed decreased phosphorylation of acetylcoenzyme A carboxylase (pACC) increased but increased PDHC phosphorylation in LKB1-deficient A549s ( Figure 1E ). This finding is consistent with a role of hypoxia inducible factor-1a (HIF-1a) in reprogramming metabolism in cells lacking functional LKB1 [5] . Computational estimation of PDHC flux and associated confidence intervals from sensitivity analyses further confirmed this finding ( Figure 1F ). Metabolic tracing with [13C]glutamine indicated there was decreased fully labeled (M+5 or M5) KG labeling in +LKB1 cells ( Figure 1G ). Despite this decrease in relative glutamine anaplerosis (entry of carbon into the TCA cycle), we noted a significant increase in KG dehydrogenase flux ( Figure 1H ) and increased ATP-linked respiration in +LKB1 cells. These results suggest that KG in LKB1-deficient cells is derived directly from glutamine via glutaminase activity, whereas cells with a WT LKB1 protein obtain KG predominantly from oxidative isocitrate dehydrogenase (IDH) flux. Additional MFA experiments were conducted in vec. and +LKB1 cells under conditions of metabolic stress, including hypoxia or matrix detachment. We have previously demonstrated that such conditions drive metabolic reprogramming through specific glucose and glutaminedependent pathways [6, 7] . While NSCLC expressing or lacking LKB1 grew at similar rates under hypoxia (Figure 2A ), [13C]glucose tracing indicated that PDHC flux was differentially affected under this condition ( Figure 2B) , with +LKB1 cells maintaining higher flux through this enzyme. Nutrient/byproduct uptake and secretion were not significantly different ( Figure 2C ), but the extent of citrate labeling from [13C]glutamine was reduced in +LKB1 cells ( Figure 2D ), suggesting these cells are less reliant on glutaminase activity than vec. control cells. Cells cultured on polyhydroxymethacrylate (pHEMA)-coated plates are unable to attach to matrix and undergo metabolic stress associated with decreased PDH flux [6] . Expression of functional LKB1 indicates that these cells are better able to maintain PDH flux ( Figure 2E ) and less reliant on glutaminase ( Figure 2F ) in response to such a stress. Time course analysis of AMPK, ACC, and PDH phosphorylation are consistent with these changes, as +LKB1 cells have increased pAMPK and pACC but decreased pPDH ( Figure 2G ). These results indicate LKB1 is critical for reprogramming cell metabolism in response to microenvironmental stress. Task 2. Observe the effects of biguanide treatment on NSCLC cell lines at physiologically relevant doses. NSCLC cell lines to be studied include the above A549 cells and a similar panel of H460 cells. Work to be performed by Hui Zhang and graduate student Seth Parker (months 6-10) 2a. Perform 13 C-tracing experiments above upon treating cells with decreasing doses of metformin and phenformin (months 6-10) 2b. Computationally resolve intracellular fluxes using the above data (months 6-10) 2c. Quantify cell survival in response to nutrient deprivation and hypoxia at the relevant does of biguanides (months 6-10)
We have conducted MFA studies tracing the reliance of NSCLC cells on glutamine for AcCoA generation in response to phenformin treatment and in the context of cells that are deficient (vec.) or proficient (+LKB1) in the LKB1 tumor suppressor.
[13C]glutamine labeling patterns indicative of oxidative glutaminolysis (blue) or reductive carboxylation (red) are depicted in Figure 3A . Phenformin drives a pronounced increase in glutaminase flux, as indicated by the extent of fully labeled (M5) glutamate from [13C]glutamine tracing ( Figure 3B ). Importantly, +LKB1 cells more proficient in synthesizing asparate from glutamine in the presence of phenformin, as evidenced by the decreased M0 and increased M3 labeling in +LKB1+phen cells ( Figure 3C ). Computational MFA was conducted on palmitate labeling and demonstrated that +LKB1 cells maintained slightly higher glucose oxidation and glutamine conversion to lipids ( Figure 3D ), providing evidence that they are better able to survive and proliferate in the presence of phenformin. In fact, +LKB1 cells were able to proliferate (albeit at a slow rate) with 50 M phenformin in the culture medium, whereas cells lacking functional LKB1 did not proliferate at all ( Figure 3D ). These results support our hypothesis that phenformin treatment and glutamine metabolism may be effective co-targets to slow LKB1-deficient tumor growth. Similar results were also observed using H460 NSCLC cells lacking or expressing functional LKB1 (not shown). Task 3. Identify the specific enzymes which catalyze glutamine anaplerosis in response to stress Work to be performed by Hui Zhang and graduate student Seth Parker (months [10] [11] [12] [13] [14] . 3a. Quantitatively compare the extent of glutamine versus glutamate uptake in NSCLC cells under stress (months 10-11) 3b. Quantify and compare fluxes through glutaminase, nucleotide synthesis, and hexosamine synthesis using [- 15 N]glutamine to determine the enzyme(s) which convert glutamine to glutamate (months [11] [12] 3c. Quantify and compare the flux of glutamate to a-ketoglutarate as catalyzed by aminotransferases and/or glutamate dehydrogenase using [- 15 N]glutamine (months 12-13) 3d. Functionally validate the effects of metabolic inhibitors of each enzyme using MFA and treatments with asparaginase, 968, BPTES, azaserine, DON, aminooxyacetate, or EGCG (months [12] [13] [14] . 5d. Evaluate the tumor burden and cell signaling profile of treated/untreated tumors through luciferase and histology analyses (months 18-23) 5e. Quantify metabolite profiles in plasma, tumors, and adjacent normal tissue using GC/MS analysis (months [18] [19] [20] [21] [22] [23] [24] This grant partially supported work on related 13C MFA projects aimed at studying the metabolic response of cells to hypoxia in the presence or absence of mutant IDH1 and IDH2. Additional studies developed a new approach for quantifying metabolic sources of NADPH regeneration in the mitochondria and cytosol. Both of which resulted in publications [8, 9] .
Key Research Accomplishments
 Identified key differences in metabolic activity in NSCLC cells lacking functional LKB1  Demonstrated key stress conditions that exacerbate the defect caused by LKB1 loss  Uncovered a mechanistic link between LKB1 activity and maintenance of PDH flux  Characterized metabolic reprogramming in response to phenformin  Explored sensitivity of LKB1-proficient and deficient cells to glutaminase inhibition under nutrient replete conditions  Demonstrated the increased dependence of hypoxic cells on both oxidative and reductive glutamine metabolism  Developed a tool for quantifying compartment-specific NADPH metabolism in the cytosol and mitochondria Two research manuscripts were published with partial support from this grant [8, 9] .
Reportable outcomes

Conclusions
Our MFA results have generated a "metabolic roadmap" highlighting the distinct metabolic changes that are caused by loss of the LKB1 tumor suppressor in NSCLC. These data indicate that LKB1-deficient cells have a propensity for using glutamine to fuel bioenergetic metabolism in the TCA cycle. We have moved beyond this basic characterization and also investigated how metabolism changes in LKB1-deficient and proficient NSCLC cells when they experience stresses that affect the energy state of cells, including hypoxia, matrix detachment, and treatment with the biguanide phenformin. These studies indicate that metabolic stress further exacerbates the metabolic differences between NSCLC cells that express or lack functional LKB1. Of particular interest is the reliance of LKB1-deficient cells on flux through the glutaminase enzyme. Inhibitors are under investigation in the clinic in some cancers, and we are now exploring the efficacy of such treatments in LKB1-deficient cells. While marginal differences in response have been observed thus far, these experiments have relied thus far on cell culture growth only. We hypothesize that the in vivo microenvironment may drive LKB1-deficient cells to be more sensitive to metabolic stress or combination treatments. Studies using xenograft models of lung tumor growth will commence in Year 2 of this grant.
Ultimately, these results can make a rapid, clinical impact by outlining specific genetic phenotypes in NSCLC that may benefit from combinatorial treatments with biguandies such as metformin (clinically used for diabetes already) or phenformin and glutaminase inhibitors. Several compounds that inhibit GLS are currently under investigation at the pre-clinical and Phase I stages (Calithera). However, metabolic treatments are likely to most effective when the specific regulatory or enzymatic defects of a given cancer are exploited as outlined here. Thus,Eukaryotic cells compartmentalize biochemical processes in different organelles, often relying on metabolic cycles to shuttle reducing equivalents across intracellular membranes. NADPH serves as the electron carrier for the maintenance of redox homeostasis and reductive biosynthesis, with separate cytosolic and mitochondrial pools providing reducing power in each respective location. This cellular organization is critical for numerous functions but complicates analysis of metabolic pathways using available methods. Here we develop an approach to resolve NADP(H)-dependent pathways present within both the cytosol and the mitochondria. By tracing hydrogen in compartmentalized reactions that use NADPH as a cofactor, including the production of 2-hydroxyglutarate by mutant isocitrate dehydrogenase enzymes, we can observe metabolic pathway activity in these distinct cellular compartments. Using this system we determine the direction of serine/glycine interconversion within the mitochondria and cytosol, highlighting the ability of this approach to resolve compartmentalized reactions in intact cells.
INTRODUCTION
One of the defining characteristics of eukaryotic cell metabolism is the compartmentalization of reactions in different organelles. Although coordination of metabolic flux across organelles is critical for cell physiology, the inability to distinctly observe identical reactions present in more than one subcellular location has been a major barrier to understanding cell metabolism. Many of these compartmentalized reactions are oxidation/reduction (redox) reactions that utilize pyridine nucleotide-based cofactors to transfer electrons between metabolites to support biosynthesis, redox homeostasis, signal transduction, and ATP generation (Pollak et al., 2007a Figure 1B) . NADPH has two hydrogens that can be transferred when it acts as an electron donor. Once labeled, either the labeled or unlabeled hydrogen atom can be transferred depending on the stereospecificity of downstream NADPH-utilizing enzymes (You, 1985 Figure S1A available online), and subsequent labeling of the second hydrogen on NADP + yields NADPH heavy by two mass units (M2) at later time points ( Figure 1B ). Some labeling of ribose-5-phosphate and ribulose-5-phosphate was also observed at late time points, presumably via flux through the nonoxidative PPP ( Figure S1B ). This label incorporation into the ribose moieties of NADP(H) could account for a minor portion of the isotope enrichment observed at 24 hr, as suggested by the small amount of M2 labeling of NADP + ( Figure S1A ) Figures 1C and 1D ). Importantly, no label from [3- 2 H]glucose was detected on citrate (see percent value in Figure 1A ), suggesting that isotope enrichment on lipids was from the NADPH pool that was labeled by the oxidative PPP. We also detected labeling of fatty acids from [1-2 H]-glucose ( Figure S1H) ; however, tracing of G6PD-derived NADPH is complicated by deuterium from [1- 2 H]glucose being retained on citrate and lipogenic acetyl-CoA ( Figure S1D Figure 2B ). Label was detected on GAP in A549 cells; however, the level of GAP in H1299 cells was below the limit of detection. In addition, no label was detected on metabolites in lower glycolysis including PEP, 3PG, and pyruvate. This pattern fits with known reactions using NADH in central carbon metabolism ( Figure 2A) Figure 2C ), as well as label on NAD+ ( Figure S3A ) arising from donation of the unlabeled hydride from M1 labeled NADH. Interestingly, we observed isotope incorporation into fatty acid pools from [4- 2 H]glucose ( Figure 2D ), suggesting that some label from NADH transfers to cytosolic NADPH through an unknown mechanism ( Figure S3F Figure S3E ). Furthermore, these direct measurements of total cellular NADP(H) cannot distinguish between cytosolic and mitochondrial pools, highlighting the need for methods to elucidate compartment-specific NADP(H) pools.
A Reporter System to Trace Compartmentalized Sources of NADPH
The above data demonstrate that we can observe cytosolic production of NADPH and NADH in intact cells. Although we were able to quantify the contribution of oxidative PPP enzymes to the lipogenic NADPH pool, deuterium tracing alone cannot distinguish other compartmentalized sources of NADPH. Therefore, we sought to develop a reporter system that can detect pathway-specific NADPH production in different subcellular compartments. To accomplish this, we took advantage of the neomorphic mutant IDH enzymes that produce (D)2-hydroxyglutarate (2HG) from aKG. This reaction reduces aKG by transferring a hydride from NADPH to form 2HG. As 2HG is a xenometabolite that is only present at very low levels in most cells (Matsunaga et al., 2012), it can be used as an endproduct readout. By applying specific metabolic 2 H-tracers to cells and measuring enrichment of 2HG produced by ectopically expressed mutant IDH1 (cytosol) or IDH2 (mitochondria), we reasoned that pathway-specific information on NADPH metabolism in each compartment could be obtained ( Figure 3A) .
We generated H1299 and A549 cell lines that express epitopetagged mutant IDH1-R132H (mtIDH1-C) or mutant IDH2-R172K (mtIDH2-M) in a doxycycline-dependent manner ( Figure S4A ). We employed a weak promoter to minimize effects on endogenous IDH metabolism. Indeed, FLAG-tagged mtIDH1-C was expressed at levels that were not detectable with an antibody recognizing wild-type IDH1 enzyme in these cells ( Figure S4A ). mtIDH1-C is expected to be expressed in the cytoplasm and mtIDH2-M in the mitochondria, and we confirmed the localization of each using cell fractionation and western blotting (Figure 3B ). We also confirmed that the FLAG-tagged mutant IDH enzymes produce 2HG in a doxycycline-dependent manner in both H1299 and A549 cell lines ( Figure 3C ). Interestingly, mtIDH1-C produced less 2HG than mtIDH2-M in cells, consistent with observations that ectopically expressed IDH2 mutants produce more 2HG than IDH1 mutants due to their mitochondrial localization (Ward et al., 2013) . In all cases, 2HG levels were far below those observed in tumor cell lines expressing endogenous mutations in IDH1 (R132C/+, HT1080) or IDH2 (R172S/+, SW1353) ( Figure 3D ). Introduction of mutant IDH enzymes could impact NADPH or TCA metabolism; however, 2HG production flux observed in cell lines expressing IDH1 mutants at higher levels is small relative to other aKG-dependent reaction fluxes, suggesting mutant IDH expression has a minimal direct impact on aKG pools (Grassian et al., 2014 
Figure 3. Generation and Characterization of Cell Lines Expressing Inducible Mutant IDH
(A) Schematic demonstrating the transfer of deuterium (red dots) from NADPH to 2HG via the reaction catalyzed by mutant IDH enzymes. mtIDH1 is localized to the cytoplasm, and mtIDH2 is localized to the mitochondria. By expressing compartment-specific mutant enzymes and combining this with deuterated glucose tracer, it is possible to track 2HG production and therefore the source of the NADPH used to make the 2HG in the cytosol or the mitochondria.
(B) Mutant IDH1-R132H is localized to the cytosol (mtIDH1-C), and mutant IDH2-R172K is localized to the mitochondria (mtIDH2-M) in H1299 and A549 cells. Cells were transduced with lentiviral constructs containing cDNA encoding C-terminal FLAG-tagged IDH1-R132H or IDH2-R172K under the control of a doxycycline (dox)-inducible promoter. Once stable cell lines were established, cells were treated with 0.1 mg/mL dox for 24 hr. Protein expression was analyzed by cellular fractionation and western blotting using antibodies against FLAG, cytochrome c (mitochondrial-specific marker), and Hsp70 (cytoplasmic-specific marker). C, Supernatant-100 fraction (cytoplasm); M, mitochondria. Samples from mtIDH1-C and mtIDH2-M cells were analyzed on separate gels. doxycycline does not significantly affect metabolism in this system. In addition, we observed no significant differences in pool sizes of NAD + , NADH, NADP + , or NADPH in H1299 mtIDH1-C and mtIDH2-M cells following the addition of doxycycline for 24 hr, suggesting that doxycycline-dependent production of 2HG was not altering the availability of these cofactors for use in other redox reactions ( Figure S4D ). This is supported by the reported k cat of mutant IDH1 enzymes being small relative to wild-type IDH1 ) and suggests that any direct effects of these enzymes on cellular redox state are minimal.
Validation of Compartment-Specific Cofactor Tracing
To validate the ability of this system to trace compartment-specific NADPH metabolism, we induced expression of the mutant IDH enzymes in cells cultured in the presence of H]glucose and measured enrichment of 2 H in the 2HG pool. In order to ensure that the cells were at or near isotopic steady state prior to induction of mutant IDH expression, the cells were incubated with tracer for 24 hr prior to the addition of doxycycline. Consistent with [3- 2 H]glucose producing cytosolic NADPH via the oxidative PPP, 2HG was only significantly labeled from H] glucose in the mtIDH1-C cell lines and not in the mtIDH2-M cell lines ( Figure 3E ). Importantly, little to no label was observed on aKG under these conditions, ensuring that label on 2HG was a direct result of hydride ion transfer from NADPH by the mutant enzyme. We next asked whether label from [4- 2 H]glucose was incorporated into 2HG by either mtIDH1-C or mtIDH2-M. Notably, more 2HG was labeled from [4- 2 H]glucose in mtIDH2-M cells than in mtIDH1-C cells ( Figure 3F ). Figure 4C ).
Characterizing Serine/Glycine Metabolism in the Cytosol and Mitochondria
We next sought to use our reporter system to examine a compartmentalized metabolic cycle. Reactions that make up folate-mediated one-carbon metabolism exist in both the cytosol and the mitochondria, although it is not clear from current literature whether these are linked in a cycle and/or in which direction the reactions proceed ( 13 C tracing is unable to ascertain the directionality, compartmentalization, and interconnectivity of this process. Indeed, upon culture with [U- 13 C 3 ]serine, we observed significant interconversion of serine and glycine in A549 mtIDH1-C and mtIDH2-M cells ( Figure 5A ). The reactions catalyzed by MTHFD1 (cytosolic) and MTHFD2/MTHFD2L (mitochondrial) utilize NAD(P)H ( Figure 5B) ; therefore, we hypothesized that 2 H serine and glycine tracing in combination with our compartment reporter system would enable us to experimentally determine the direction of serineglycine exchange reactions in the cytosol and mitochondria. Hydrogens on carbon-3 of serine are transferred to 5,10-methylenetetrahydrofolate (5,10-methyleneTHF) and subsequently to NADPH via MTHFD1/2 ( Figure 5B) . Additionally, the glycine cleavage system (GCS) exists in the mitochondria and could transfer hydrogen from carbon two of glycine to 5,10-methylene-THF and generate NADPH ( Figure 5B ) (Kikuchi et al., 2008) .
To study these compartment-specific pathways, we cultured A549 mtIDH1-C and mtIDH2-M cells with either [ Figure 5C ), indicating that either the majority of mitochondrial glycine is generated by SHMT2 (rather than glycine import) or the label is lost in the GCS. Consistent with the lack of label transfer from 2 H-labeled serine or glycine to 2HG in mtIDH1-C cells, we detected minimal contribution of these tracers in the lipogenic NADPH pool ( Figure 5D ). (Figure 3E) . Collectively, these data provide direct evidence that serine metabolism can contribute to regenerating mitochondrial NADPH in cells.
DISCUSSION
We have developed a system that can distinguish compartmentalized pools of NADPH, demonstrating the directionality and interconnectivity of serine/glycine metabolism in the cytosol and mitochondria of intact cells. In the cells studied, conversion of serine to glycine occurs primarily in the mitochondria with the reaction catalyzed by MTHFD2/MTHFD2L contributing to NADPH production in this compartment. Interestingly, label transfer from both [2,3, isozymes in such processes, adaptation to genetic depletion strategies that break these cycles can confound interpretation. The reporter system described here circumvents these issues for reactions involving NADPH by providing direct visualization of compartmentalized reaction activity and direction in intact cells. 
The remaining supernatant containing cytoplasmic and membrane proteins was centrifuged for 1 hr at 100,000 3 g. The supernatant from this final spin represents the S100 fraction. Protein expression was analyzed by western blotting using antibodies against FLAG (DYKDDDDK tag, Cell Signaling), IDH1 (Santa Cruz), IDH2 (Abcam), Cytochrome C (clone 7H8.2C12, Abcam), Hsp 70 (Cell Signaling).
Metabolite Extraction and GC-MS Analysis
Polar metabolites and fatty acids were extracted using methanol/water/chloroform as previously described (Metallo et al., 2012) . Parental and pSLIKmtIDH cells were cultured in 6-well or 12-well plates, and volumes of tracer media and extraction buffers were adjusted accordingly. Derivatization of both polar metabolites and fatty acids has been described previously (Metallo et al., 2012) . Briefly, polar metabolites were derivatized to form methoximetBDMS derivatives by incubation with 2% methoxylamine hydrochloride (MP Biomedicals) in pyridine (or MOX reagent (Thermo Scientific) followed by addition of N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) with 1% tert-butyldimethylchlorosilane (t-BDMCS) (Regis Technologies). Nonpolar fractions, including triacylglycerides and phospholipids, were saponified to free fatty acids and esterified to form fatty acid methyl esters by incubation with 2% H 2 SO 4 in methanol. Derivatized samples were analyzed by GC-MS using a DB-35MS column (30 m 3 0.25mm i.d. 3 0.25 mm, Agilent J&W Scientific) installed in an Agilent 7890A gas chromatograph (GC) interfaced with an Agilent 5975C mass spectrometer (MS). Mass isotopomer distributions were determined by integrating metabolite ion fragments (Table S1 ) and corrected for natural abundance using in-house algorithms adapted from Fernandez et al. (1996) .
Extraction of NAD+, NADH, NADP+, and NADPH and Analysis by LC-MS/MS
The extraction protocol for NADPH was based on one previously described by MA) with an UFLC XR HPLC (Shimadzu, Columbia, MD) coupled to an AB SCIEX Qtrap 5500 mass spectrometer (AB SCIEX, Framingham, MA) operating in negative ion mode. Mass isotopomer distributions were corrected for natural abundance using in-house software adapted from Fernandez et al. (1996) . Additional information regarding chromatographic separation, mass spectrometry, and data acquisition can be found in the Supplemental Experimental Procedures.
Isotopomer Spectral Analysis
The ISA method compares a measured palmitate mass isotopomer distribution to one that is simulated using a reaction network for palmitate synthesis whereby 14 NADPH molecules are consumed to form one palmitate molecule. Models were also generated for myristate and stearate synthesis whereby 12 or 16 NADPH molecules are consumed to form one myristate or stearate molecule, respectively. Parameters for the relative enrichment of the lipogenic NADPH pool from a given [ 2 H] tracer and the percentage of fatty acids that are de novo synthesized are extracted from a best-fit model using the INCA MFA software package ( Figure S2 ) (Young, 2014) . The 95% confidence intervals for both parameters were estimated by evaluating the sensitivity of the sum of squared residuals between measured and simulated palmitate mass isotopomer distributions to small flux variations .
Cell Proliferation Assays
On day À1, 1/10 of a confluent 10 cm dish of cells was seeded in six 6-wells of a 6-well plate. Twenty-four hours later, cells were counted on an automated cell counter (Nexcelom), and this time point was considered T 0 . At T 0 , all other time points were media changed to ± doxycycline media (0. 
Abstract
Oncogenic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in several types of cancer, but the metabolic consequences of these genetic changes are not fully understood. In this study, we performed
Introduction
Mutations in the metabolic enzymes isocitrate dehydrogenase 1 and 2 (IDH1/2) have been identified in a variety of tumor types, including acute myelogenous leukemia (AML), gliomas, cholangiocarcinomas, and chondrosarcomas (1-9). These mutations are almost exclusively heterozygous point mutations that occur in specific residues within the catalytic pocket, and are suggestive of activating, oncogenic mutations. Although IDH mutants are no longer capable of efficiently carrying out the normal oxidative reaction [converting isocitrate and NADP þ to a-ketoglutarate (aKG), CO 2 , and NADPH), IDH mutations result in a novel gain-of-function involving the reductive, NADPHdependent conversion of aKG to (D)2-hydroxyglutarate (2-HG; refs. 10, 11). 2-HG is not typically present at high levels in normal cells but accumulates considerably in cells with IDH1/2 mutations as well as in the tumors of patients with IDH1/2 mutations, and has thus been termed an "oncometabolite" (10) (11) (12) .
Research into the oncogenic function of mutant IDH1/2 has focused in large part on the effects of 2-HG. Numerous reports have linked 2-HG accumulation to epigenetic changes, which are thought to contribute to alterations in cellular differentiation status (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Additional mutant IDH phenotypes have also been reported, including changes in collagen maturation and hypoxia inducible factor-1a (HIF1a) stabilization (21, 23) . These changes likely occur through inhibition of aKG-dependent dioxygenase activity by high levels of 2-HG. However, the diverse roles that aKG-dependent dioxygenases play in the cell and the numerous phenotypes associated with mutant IDH and 2-HG suggest that the phenotypes downstream of 2-HG induction could be cell type-or context-specific. We hypothesize that metabolic alterations induced by IDH mutations may also be present and might be a general phenotype that offers additional approaches to target these tumors. Previous work suggests that overexpression of mutant IDH alters the levels of several metabolites (24) and leads to increased sensitivity to glutaminase inhibitors (25) . Studies by Leonardi and colleagues have indicated that the IDH1-mutant enzymes compromise the ability of this enzyme to catalyze the reductive carboxylation reaction (26) . However, it is unclear how IDH mutations affect central carbon metabolism in the heterozygous cellular setting, and further exploration into how these metabolic differences could be therapeutically exploited is warranted. An important distinction between IDH1 and IDH2 is their localization in the cytosol/peroxisome and Systems-based approaches that use stable isotope tracers (e.g., [
13 C]glutamine), mass spectrometry, and network modeling to estimate metabolic fluxes offer a unique means of characterizing intracellular metabolism (27) . To understand the metabolic impact of heterozygous IDH mutation in vitro, we have applied 13 C metabolic flux analysis (MFA) to a panel of cell lines that differ only with respect to their IDH1-and IDH2-mutant status. Using this approach, we have characterized how cells with wildtype (WT) and mutant IDH1/2 respond to hypoxia and pharmacologic induction of mitochondrial dysfunction.
Materials and Methods
Cell culture
HCT116 and MCF-10A isogenic clones were obtained from Horizon Discovery Ltd and IDH1/2 mutational status was verified by sequencing (28) . HCT116 cells were cultured in McCoy's 5A Modified Medium with 10% FBS. D-2-HG treatments were done at 10 mmol/L and replenished every 48 hours. MCF-10A cells were cultured as described previously (28) . HT-1080, SW1353, A549, and 143B cells were cultured in DMEM supplemented with 10% FBS. HT-1080 and SW1353 cells were obtained from the ATCC, and cells were tested and authenticated by single-nucleotide polymorphism fingerprinting. A549 cells were obtained from ATCC and were not further tested or authenticated. 143B cells were kindly provided by Dr. Leonard Guarente (Massachusetts Institute of Technology, Cambridge, MA) and were not further tested or authenticated. Cells were routinely cultured in normoxia (21% O 2 ) and then moved to hypoxia (1%-3% O 2 , as indicated in the figure legends) for 48 to 72 hours where indicated. Generation of the r 0 cells is described in the Supplementary Methods. Xenograft assays are described in Supplementary Methods.
Steady-state labeling of organic, amino, and fatty acids was accomplished by culturing subconfluent cells in triplicate in tracer medium for 72 hours in a 6-well plate. Labeling studies of HCT116, SW1353, HT1080, A549, and 143B cells were performed in glucose or glutamine-free DMEM containing 10% FBS and 17.5 mmol/L [1,2- C 5 ]glutamine, 5% horse serum, 20 ng/mL EGF, 10 mg/mL insulin, 0.5 mg/mL hydrocortisone, and 100 ng/mL cholera toxin. Gas chromatography mass spectrometry (GC-MS) analysis is described in Supplementary Methods.
MFA
13
C MFA was conducted using INCA, a software package based on the EMU framework (http://mfa.vueinnovations. com; ref. 29) . Intracellular concentrations of free metabolites and intra-and extracellular fluxes were assumed to be constant over the course of the tracing experiment. Fluxes through a metabolic network comprising of glycolysis, the pentose phosphate pathway, the TCA cycle, biomass synthesis, and fatty acid synthesis were estimated by minimizing the sum of squared residuals between experimental and simulated MIDs and extracellular fluxes using nonlinear least squares regression (30) . The best global fit was found after estimating 100 times using random initial guesses for all fluxes in the network. A c 2 statistical test was applied to assess the goodness-of-fit using a of 0.01. The 95% confidence intervals for all fluxes in the network were estimated by evaluating the sensitivity of the sum of squared residuals to flux variations (30) . Isotopomer Spectral Analysis was performed as previously described (31) . See Supplementary Methods for further details of MFA.
Reagents
The following reagents were used at the doses indicated and as described in the text/figure legends: [1,2-13 C 2 ]glucose, [3- 
Determination of oxygen consumption
HCT 116 cells were grown at either normoxia or hypoxia (3% O 2 ), and respiration was measured using an XF e 96 analyzer (Seahorse Bioscience). Cell growth and assays at 3% O 2 were conducted using the Coy Dual Hypoxic Chambers for Seahorse XF e Analyzer (Coy Laboratory Products, Inc.) as described in Supplementary Methods.
Proliferation assays
To calculate doubling time, cells were trypsinized and viable cells were quantified on a ViCell (Beckman-Coulter). Doubling times are presented as the average of three or more independent experiments.
To generate longer-term growth curves, cells were plated at 3,000 cells per well in a 96-well plate in triplicate. Twenty-four hours later, the indicated treatment was started and confluency measurements were taken every 12 hours for 108 to 216 hours using an Incucyte Kinetic Imaging System (Essen BioScience). Confluency data were modeled using a generalized logistic growth equation (equation 1), and the maximum growth rate was estimated using nonlinear regression:
where U and L represent upper and lower asymptotes, t 0 represents the time at which cell confluency reaches 50%, and m max represents the maximum growth rate per hour. Pharmacologic profiling of the CCLE was performed as previously described (32) . The growth inhibition assays are described in Supplementary Methods.
Statistical analysis
All results shown as averages of multiple independent experiments are presented as mean AE SE; results shown as averages of technical replicates are presented as mean AE SD. P values were calculated using a Student two-tailed t test;
Ã , P value between 0.005 and 0.05; ÃÃ , P value between 0.001 and 0.005; ÃÃÃ , P value <0.001. All errors associated with MFA and ISA of lipogenesis are 95% confidence intervals determined via sensitivity analysis.
Results
Mutant IDH1 compromises metabolic reprogramming under hypoxia
We and others have previously demonstrated that tricarboxylic acid (TCA) metabolism is reprogrammed under hypoxia, and flux through WT IDH1 and/or IDH2 become critical in these contexts (31, (33) (34) (35) (36) (37) . Oncogenic mutations in IDH1 and IDH2 mitigate these enzymes' WT function and, in particular, the ability to catalyze the reductive carboxylation reaction while inducing a neomorphic activity that results in the accumulation of D-2-HG (11, 26) . Therefore, we hypothesized that cancer cells harboring mutations in either IDH1 or IDH2 may be compromised in their ability to modulate metabolism under low oxygen tensions. To identify metabolic liabilities induced by IDH1 mutations, we applied 13 C MFA to isogenic HCT116 colon cancer cells with WT IDH1/2 (parental) or a heterozygous IDH1 mutation, IDH1 R132H/þ (clone 2H1). The IDH1-mutant, but not WT, cells have previously been shown to produce high levels of 2-HG (28). To gauge relative flux through the TCA cycle, each cell line was cultured in the presence of [U- 13 C 5 ]glutamine (uniformly 13 C-labeled glutamine) under normoxic or hypoxic (2% oxygen) conditions for 72 hours, and isotope enrichment in various metabolites was determined via mass spectrometry (Fig. 1A) . Both cell lines displayed decreased oxidative TCA flux (as evidenced by decreased M3 aKG) in hypoxia ( Supplementary Fig. S1A ). Although minimal changes in labeling were detected when comparing the mass isotopomer distribution (MID) of citrate in each cell type grown in normoxia (designated as M0, M1, M2, etc. mass isotopomers, corresponding to ion fragments containing zero, one, or two 13 C, respectively), more significant deviations occurred in cells proliferating under hypoxia (Fig.  1B) . Parental cells under hypoxia exhibited increased M5 labeling indicative of reductive carboxylation (Fig. 1B) , as has been seen previously for many WT IDH1/2 cell lines (31, 33, 35) . In contrast, the IDH1 R132H/þ cells showed only a slight increase in the abundance of this mass isotopomer under hypoxia (Fig. 1B) . M5 citrate can also be produced via M6 citrate and glutaminolysis (38) ; however, no increase in the low basal levels of M6 citrate was observed in hypoxia (Fig. 1B) . We observed similar changes in the labeling of other TCA metabolites, including M3 fumarate, malate, and aspartate (derived from oxaloacetate), further supporting our finding that IDH1-mutant cells display compromised reductive glutamine metabolism in hypoxia ( Fig. 1A and Supplementary Fig. S1B-S1D ). To further quantify the metabolism of glutamine through the reductive carboxylation pathway in these cells, we determined the contribution of [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamine to palmitate synthesis using isotopomer spectral analysis (ISA), as this tracer specifically labels acetyl coenzyme A (AcCoA) through the reductive carboxylation pathway (Fig. 1A; ref. 39) . Although parental cells increased the contribution of glutamine to lipogenic AcCoA almost 5-fold under hypoxia, cells with a mutant IDH1 allele were compromised in their ability to increase this reductive carboxylation flux (Fig. 1C) .
To characterize the metabolic phenotype of HCT116 cells with WT or IDH1 R132H/þ in a more comprehensive and unbiased manner, we incorporated uptake/secretion fluxes and mass isotopomer data into a network of central carbon metabolism. This model included glycolysis, the pentose phosphate pathway (PPP), TCA metabolism, and various biosynthetic fluxes using [U- 13 C 5 ]glutamine and [1,2-13 C 2 ]glucose (for the oxidative PPP bifurcation), as these tracers provide optimal flux resolution throughout central carbon metabolism (40) . An elementary metabolite unit (EMU)-based algorithm was used to estimate fluxes and associated confidence intervals in the network (41, 30) , and a detailed description of the model, assumptions, and the complete data set are included as Supplementary Material. As expected, glucose and lactate fluxes were significantly increased by hypoxia in both cell lines, and significant 2-HG secretion occurred only in IDH1 R132H/þ cells (Fig. 1D) . Notably, 2-HG secretion was elevated under hypoxia, consistent with previous observations of 2-HG accumulation at low oxygen tension (33) .
The modeling data comparing parental HCT116 cells grown in normoxia and hypoxia highlight some of the important metabolic changes that occur at low oxygen tensions (Fig. 1E-I,  Supplementary Fig. S2, and Supplementary Tables S1-S4 ). In the HCT116 parental cells, pyruvate dehydrogenase and oxidative TCA metabolism are decreased under hypoxia, whereas pyruvate cycling through malic enzyme (ME) and pyruvate carboxylase (PC) are elevated under these conditions. Parental cells increased reductive IDH flux several fold, such that net IDH flux slightly favored the direction of reductive carboxylation (Fig. 1F, G, and I) . As with the MID changes (Fig. 1B) , only modest changes in metabolism were detected when comparing parental HCT116 cells with IDH1 R132H/þ 2H1 grown under normoxia (Fig. 1E-H and Supplementary Tables S1-S4 ). However, mutant cells maintained high oxidative IDH and aKG-dehydrogenase (aKGDH) fluxes and were unable to induce reductive carboxylation under hypoxia relative to the parental cells (Fig. 1E-G, I , and Supplementary Tables S1-S4). This oxidative TCA flux was maintained by increased glutamine anaplerosis and flux through ME and PC (Fig. 1H and I and Supplementary Tables S1-S4). Overall, these results demonstrate that significant reprogramming of TCA metabolism occurs in cells at 2% oxygen, and expression of IDH1 R132H/þ abrogates the cells' ability to respond appropriately to hypoxic stress.
Compromised reductive TCA metabolism is specific to cells with mutant IDH1
The MFA results above suggest that heterozygous IDH1 mutations disrupt the metabolic response of cells to hypoxic stress. To determine whether this metabolic deficiency is common to cells with either IDH1 or IDH2 mutations, we interrogated a panel of previously reported IDH1-and IDH2-mutant isogenic cells (28) and measured the ability of each to initiate reductive carboxylation under 2% oxygen. With the exception of IDH2 R140Q/þ cells, these mutant cell lines exhibit a !25-fold increase in 2-HG compared with parental HCT116 cells (28) . We cultured each clone with [U- 13 C 5 ]glutamine under normoxia and hypoxia, quantifying M5 citrate abundance (see Fig. 1A ) to determine the relative extent of reductive carboxylation induction. All but one of the IDH1-mutant clones were consistently compromised in their ability to increase reductive carboxylation activity under hypoxia (Fig. 2A) . The one exception being the IDH1 R132H/þ 2C11 clone, which showed a weaker phenotype relative to the other IDH1-mutant clones ( Fig. 2A) . This is likely explained by a lower level of IDH1 R132H protein (Fig. 2B ) and lower level of 2-HG than the IDH1 R132H/þ 2H1 clone (28) .
Unlike mutant IDH1 cells, HCT116 cells with IDH2 mutations exhibited levels of M5 citrate under hypoxia that were comparable with the parental cells ( Fig. 2A) . Addition of 10 mmol/L D-2-HG to the culture media also had a minimal effect on TCA metabolism (Fig. 2A) . These data suggest that high 2-HG levels alone are unable to inhibit reductive carboxylation activity, even though this dose of exogenous D-2-HG is suffi- cient to induce the 2-HG-dependent epithelial-mesenchymal transition (EMT) phenotype previously described in these cell lines (28) . Consistent changes were observed when normalizing M5 citrate to M5 glutamate ( Supplementary  Fig. S3A ), and levels of M6 citrate were not high in any of the clones ( Supplementary Fig. S3B ), providing evidence that such changes are specific to the IDH/aconitase node of metabolism. Similar trends were also observed when measuring the ratio of aKG/citrate under normoxia and hypoxia (Fig. 2C) , another metric that describes the extent of reductive versus oxidative IDH flux (36, 42) . Finally, the contribution of glutamine to lipogenic AcCoA under hypoxia was significantly lower in cells with IDH1 mutations but not those with IDH2 mutations or exogenous 2-HG (Fig. 2D) . Overall, the extent that each IDH1-mutant cell line produced 2-HG correlated with their ability to activate reductive carboxylation flux under hypoxia (Fig. 2E) , whereas IDH2-mutant cells did not adhere to this trend. We next conducted shRNA-mediated knockdown of IDH1 and IDH2 in parental HCT116 cells to examine the roles of WT IDH1 and IDH2 in mediating reductive glutamine metabolism ( Supplementary Fig. S3C and S3D) . Knockdown of IDH1 decreased levels of M5 citrate in cell populations cultured with [U- 13 C 5 ]glutamine, whereas cells expressing shRNAs targeting IDH2 exhibited the same or higher M5 citrate (Fig. 2F) . These results are consistent with previous studies in other cell lines (31) , highlighting the importance of WT IDH1 expression in reprogramming TCA metabolism under hypoxia, and further suggest that IDH1 mutation selectively impedes WT IDH1 function in these cells.
To determine whether this mutant IDH1-induced metabolic deficiency is specific to the HCT116 genetic background or more broadly applicable to cells of different tissue origin, we performed similar analyses using MCF-10A immortalized mammary epithelial cells with heterozygous IDH1 mutations (28) . When cultured for 3 days under normoxia or hypoxia, two distinct IDH1 R132H/þ clones were compromised in their ability to generate M5 citrate or lipogenic AcCoA from [U- Cells with endogenous IDH1 and IDH2 mutations respond differently to mitochondrial stress To examine whether these trends are observed in cell lines from cancers with endogenous IDH mutations, we evaluated the ability of two cell lines harboring IDH1 or IDH2 mutations to activate reductive carboxylation under conditions of mitochondrial stress. When switched to hypoxic growth, HT1080 IDH1 R132C/þ fibrosarcoma cells exhibited a significantly decreased ability to induce reductive glutamine metabolism in comparison with SW1353 IDH2 R172S/þ chondrosarcoma cells (Fig. 3A and Supplementary Fig. S4A ). HT-1080 cells also used less glutamine for de novo lipogenesis than the SW1353 cells in 1% oxygen tension (Fig. 3B) . Thus, a cell line with an endogenous mutation in IDH1, but not IDH2, displays compromised reductive glutamine metabolism in hypoxia.
In addition to low oxygen tensions, an alternative means of inducing reductive TCA metabolism is through the inhibition of oxidative phosphorylation (OXPHOS; refs. 34, 42) . To compromise OXPHOS, we generated r 0 cells that lack a functional electron transport chain (ETC) from various cell lines using established methods (43) . As expected, oxidative mitochondrial metabolism was virtually extinguished, as evidenced by M3 and M3/M5 labeling of aKG in r 0 cells generated from IDH-mutant cells (HT1080 and SW1353) or other cancer cell lines with WT IDH1/2 (143B osteosarcoma, A549 non-small cell lung cancer; Supplementary Fig. S4B-S4E ). However, HT1080 IDH1 R132C/þ r 0 cells were compromised in their ability to generate citrate and palmitate through reductive glutamine metabolism, whereas SW1353 and both of the IDH1/2 WT r 0 cell lines were able to efficiently induce reductive carboxylation and use glutamine for lipid synthesis (Fig. 3C-F) . Both the HT1080 and SW1353 r 0 cells continued to use glucose for lipid synthesis, and this contribution was higher in the HT1080 r 0 cells (Fig. 3D) . The increased glucose utilization in HT1080 r 0 cells compared with SW1353 r 0 cells was facilitated by anaplerosis through pyruvate carboxylase, as demonstrated by increased labeling in TCA intermediates from [3- 13 C]glucose ( Supplementary  Fig. S4F and S4G) . These results provide evidence that hypoxia and mitochondrial dysfunction drive reprogramming of the TCA cycle, and cells with spontaneously acquired IDH1 mutations are unable to efficiently reprogram metabolism to induce reductive glutamine carboxylation.
Mutant IDH1 affects TCA metabolism in vivo
The metabolic deficiencies of IDH1-mutant cells occur at oxygen tensions that are likely to occur in solid tumors and some normal tissues (44) . To determine whether these metabolic phenotypes arise in vivo, we generated subcutaneous xenografts using parental, IDH1 R132H/þ 2H1, and IDH1 R132C/þ 2A9 HCT116 cells. After tumors achieved a minimum diameter of 0.8 cm, mice were infused with [1- 13 C]glutamine for 6 hours to achieve steady-state isotope enrichment in plasma and tumor ( Fig. 4A and B; ref. 45) . A targeted metabolomic analysis was performed on plasma and tumor extracts to quantify isotope enrichment and metabolite abundances. Significant 2-HG was detected only in the IDH1-mutant tumors (Fig. 4C) . Insufficient isotope enrichment was achieved in plasma and intratumoral glutamine/aKG to detect label on citrate via reductive carboxylation (Fig. 4A, B, and D) . However, in agreement with the results obtained from in vitro studies, the aKG/citrate ratio was significantly lower in IDH1-mutant tumors compared with those generated using parental HCT116 cells (Fig. 4E) , indicating that TCA metabolism may also be perturbed in tumors comprised of IDH1-mutant cells. In addition, the contribution of glutamine anaplerosis to the aKG pool was significantly elevated in IDH1 R132H/þ and IDH1 R132C/þ tumors (Fig. 4F) , which was also observed in our MFA results ( Fig. 1H and I) . Thus, the available data are consistent with our in vitro MFA results and provide evidence that TCA metabolism is similarly compromised by IDH1 mutations in vivo.
Inhibition of mutant IDH1 does not rescue reprogramming of TCA metabolism
One possible explanation for the decrease in reductive carboxylation flux in IDH1-mutant cells is that localized substrate (aKG and NADPH) consumption by the mutant enzyme for production of 2-HG compromises this activity. Therefore, we examined whether pharmacologic inhibition of mutant IDH1 could increase reductive carboxylation activity and rescue the ability of cells to use this pathway for growth under hypoxia. To test this hypothesis, we treated IDH1 R132H/þ 2H1 or IDH1 R132C/þ 2A9 cells with a mutant IDH1 inhibitor (IDH1i A) similar to a previously described structural class ( Fig. 5A; refs. 22, 46) . Doses of 10 mmol/L were able to decrease 2-HG levels more than 25-fold in both clones (Fig. 5B) . As would be expected from an engineered cell line that does not exhibit growth dependence on mutant IDH1 or 2-HG, 10 mmol/L of IDH1i A had no appreciable effect on the growth rate of either cell line (Fig.  5C ). Both short-term (3 day) and long-term (31 day) treatment with 10 mmol/L IDH1i A induced minimal changes in metabolite abundances beyond 2-HG (Fig. 5D ) and effectively reversed the mutant IDH-dependent EMT phenotype exhibited by these cells (Supplementary Fig. S5A ).
IDH1i A did not rescue the ability of cells to initiate reductive TCA metabolism under hypoxia, as labeling of citrate (Fig. 5E ) and other metabolites ( Supplementary Fig. S5B-S5D ) from (Continued.) F, aKG/citrate ratio from cells cultured as in Fig. 5D . G, contribution of [U- Other indices of reductive TCA metabolism, including the ratio of aKG/citrate and contribution of glutamine to lipid biosynthesis, also indicated that IDH1i A failed to rescue reductive carboxylation flux in these cells (Fig. 5F and G) . At 10 mmol/L, the dose that showed maximal 2-HG inhibition, IDH1i A mildly inhibited reductive carboxylation in the WT parental cells ( Supplementary Fig. S5E and S5F) , potentially due to offtarget effects on WT IDH1 at high concentrations. To further address this issue, we also treated the IDH1-mutant cells with an additional inhibitor of mutant IDH1 at more moderate concentrations (Fig. 5H) . We again observed no rescue in reductive glutamine metabolism (Fig. 5I-K) , providing evidence that inhibition of IDH1-mutant activity may be insufficient to remove the block in metabolic reprogramming in response to hypoxic stress.
Cells expressing mutant IDH1 are sensitive to pharmacologic inhibition of mitochondrial oxidative metabolism
In comparing the growth rates of the HCT116 panel under normoxia and hypoxia, we observed that mutant IDH1 cells grew more poorly under conditions of low oxygen tension than parental cells or those expressing mutant IDH2 (Fig.  6A) . HCT116 IDH1-mutant xenografts also grew at a significantly slower rate than the HCT116 parental cells (Fig. 6B) , conditions that exhibited significant stabilization of HIF1a in both parental and IDH1-mutant tumors (Fig. 6C) . The growth rate of IDH2-mutant cells as xenografts was also significantly decreased relative to the parental cells (Supplementary Fig. S6A ), though our available data do not yet support a hypothesis for how IDH2 mutations affect in vivo growth.
The slow growth of IDH1-mutant cells in the xenograft model suggests that altered TCA metabolism may contribute to the slower growth of these cells under the decreased oxygen levels in vivo. IDH1-mutant cells also exhibited increased oxidative TCA metabolism under hypoxia compared with parental cells (Fig. 1E and I) , providing evidence that they are more dependent on OXPHOS. To further confirm this phenotype, we measured oxygen consumption in parental and IDH1-mutant cells under both normoxia and hypoxia. Consistent with our MFA results, basal respiration was not significantly altered in parental and IDH1-mutant cells under normoxic conditions, though uncoupled respiration was decreased in the IDH1-mutant cells (Supplementary Fig. S6B-S6E) . Notably, mutant IDH1 cells exhibited significantly higher oligomycin-sensitive oxygen consumption under hypoxia compared with parental HCT116 cells, an effect not reproduced under normoxia (Fig. 6D and E and Supplementary Fig. S6F and S6G) . Therefore, we hypothesized that, as with growth in hypoxia, cells harboring IDH1 mutations may be more susceptible to inhibition of oxidative mitochondrial metabolism than cells with WT IDH1/2 or mutant IDH2.
To address this question, we cultured parental HCT116 cells and three IDH1-mutant clones in the presence of several compounds that inhibit Complex I of the ETC and OXPHOS. Confluency measurements were taken every 12 hours, and the maximum specific growth rate of each cell was determined using a generalized logistic growth model and compared with vehicle treatment for each cell line (Fig. 6F) . The proliferation rate of cells with mutant IDH1 was significantly more affected than that of parental HCT116 cells in response to discreet dose ranges of Complex I inhibitors. On the other hand, the IDH2 R172K/þ cells displayed no such increased sensitivity with the same treatments ( Supplementary Fig. S6H ). This altered sensitivity is not due to differences in target modulation, as 100 nmol/L rotenone effectively shut down oxidative TCA cycle flux in all cells tested ( Supplementary Fig. S6I ). Treatment of parental HCT116 cells with 100 nmol/L rotenone also induced reductive carboxylation, whereas R132H/þ 2H1 and R132C/þ 2A9 HCT116 cells were less able to increase flux through this pathway ( Supplementary Fig. S6J and S6K). Treatment with Antimycin A, an inhibitor of Complex III of the ETC, also inhibited oxidative TCA metabolism (Supplementary Fig. S6L ). Induction of reductive carboxylation by Antimycin A was observed in the parental, but not IDH1-mutant, cells (Supplementary Fig. S6M and S6N ). However, this compound had differential effects on succinate labeling compared with rotenone ( Supplementary Fig. S6O ). Notably, IDH1-mutant cells did not exhibit increased sensitivity to Antimycin A (Supplementary Fig. S6P ), suggesting that Complex III inhibition suppresses growth through distinct mechanisms compared with Complex I inhibitors (e.g., reactive oxygen species generation, and pyrimidine synthesis; ref. 43 ). Thus, these data indicate that IDH1-, but not IDH2-, mutant cells are selectively sensitive to Complex I inhibitors.
To determine whether IDH1 mutants are generally more sensitive to other treatments, we examined the effect of the cell-cycle inhibitor flavopyridol in the HCT116 panel of cells. IDH1-mutant cells did not display increased sensitivity in comparison with parental or IDH2-mutant cells (Supplementary Fig. S6Q ), further suggesting that the differential sensitivity we observe is specific to inhibitors of mitochondrial metabolism. These results indicate that oncogenic IDH1 mutations induce cells to rely more heavily on Complex I of the ETC, rendering these cancer cells more susceptible to inhibition of Finally, to evaluate whether these results are relevant to other cells, we interrogated the Cancer Cell Line Encyclopedia (CCLE; ref. 32) , which contains compound sensitivity data across more than 500 cell lines for four ETC inhibitors ( Fig. 6G; ref. 47 ). Cell lines clustered well into sensitive and insensitive groups, suggesting these compounds show consistent behavior across a wide panel of cell lines. Notably, IDH1-mutant HT1080 cells fell into the sensitive group, whereas IDH2-mutant SW1353 cells fell into the insensitive group (Fig. 6G) . The differential effects of mitochondrial metabolism inhibitors were not likely due to HT1080 being generally more sensitive to compound treatments, as the sensitivities of HT1080 and SW1353 to a broad array of more than 1,300 compounds were within one SD of each other ( Supplementary Fig. S6R ). Furthermore, HT1080 cells were significantly more sensitive than SW1353 cells to phenformin treatment, a compound that was not included in the CCLE screening set (Fig. 6H) . Together, these data indicate that IDH1 mutation may substantially sensitize cells to inducers of mitochondrial stress.
Discussion
Since the discovery of oncogenic mutations in IDH1 and IDH2, significant efforts have been made to elucidate the mechanisms driving tumorigenesis in these cancers. Owing to the accumulation of D-2-HG in these tumors, researchers have focused on the role of this oncometabolite in regulating the phenotype of IDH1/2-mutant cancer cells. For example, high D-2-HG levels and other metabolites regulate the activity of aKG-dependent dioxygenases that control many distinct cellular processes (12) . However, the diverse roles of these enzymes in mediating activities ranging from collagen hydroxylation and HIF stabilization to epigenetics regulation complicate identification of the specific process(es) driving tumorigenesis in each tumor type.
Despite the central role of these enzymes in cellular metabolism, surprisingly few investigations have addressed the metabolic changes that occur as a result of these genetic modifications. Here, we find that IDH1 mutations cause cells to increase flux through the oxidative TCA cycle, increase respiration, and compromise the conversion of glutamine to citrate, AcCoA, and fatty acids under hypoxia compared with those with WT IDH1 (Fig. 7) . Others have previously shown that IDH1-mutant proteins are biochemically compromised with respect to this latter functionality, suggesting that cells harboring such mutations may be similarly defective under certain conditions (26) . However, the cellular consequences of this effect have not been well characterized within intact, heterozygous, IDH-mutant cells. Proliferating cells must double their membrane lipids to successfully complete cell division, and evidence suggests that tumors may rely more on de novo lipogenesis than do nonneoplastic tissues, and inhibition of lipid synthesis decreases tumor growth in vivo (48, 49) . In addition, AcCoA is an important precursor for a number of other molecules, including cholesterol, phospholipids, amino acid modifications, and histone acetylation (50) . Interestingly, previous studies have also found that overexpression of mutant IDH leads to a decrease in N-acetyl amino acids, and these changes were also observed when comparing WT human glioma tissue with that of tumors with mutant IDH1 (24) . This suggests that other AcCoA-dependent molecules may be similarly perturbed in the IDH1-mutant setting. Our application of MFA to IDH1-mutant cells builds upon these results by addressing the functional consequences of heterozygous IDH1 mutations and in particular the metabolic limitations that arise in tumors cells with these genetic modifications. Given the importance of each of these AcCoA-dependent processes for Research.
on June 3, 2014. © 2014 American Association for Cancer cancerres.aacrjournals.org Downloaded from cellular homeostasis and proliferation, we speculate that the reduced metabolic flexibility of these cells contributes to the decrease in growth rate that we observe in the IDH1-mutant cells under conditions of decreased oxidative mitochondrial metabolism.
Although 2-HG-mediated control of aKG-dependent dioxygenase activity clearly plays a role in tumorigenesis driven by IDH mutations (13) (14) (15) (16) (17) (18) (20) (21) (22) (23) , our results provide insights into therapeutic strategies that exploit the metabolic vulnerabilities caused by partial loss of WT IDH1 function. Interestingly, we observe that IDH1-mutant cells do not exhibit pronounced metabolic differences in normoxia; however, growth in low oxygen tensions or with pharmacologic inhibitors of mitochondrial metabolism results in the emergence of dramatic metabolic changes. Our MFA results identify several enzymes and pathways that are altered under hypoxia and in particular in the context of IDH1 mutations. Although compartmentspecific IDH fluxes cannot be resolved with these data, these findings further highlight the importance of WT IDH1 activity in mediating reductive glutamine metabolism. Importantly, our results provide evidence that IDH1 mutations functionally compromise cellular metabolism under conditions of low oxygen levels, with the most pronounced effects being increased dependence on oxidative mitochondrial metabolism and an inability to induce reductive glutamine metabolism. We artificially induced such stresses using pharmacologic inhibitors of Complex I or manipulation of the oxygen tensions, and observed selective growth rate reductions in several IDH1-mutant cells, but not in parental or IDH2-mutant cancer cells. Other recent studies have also highlighted the importance of oxidative mitochondrial metabolism for tumor cell growth and survival both in vitro and in vivo (45, 51) .
These results suggest that compromised IDH1 function may affect the proliferative capacity of tumor cells and furthermore that IDH1-mutant tumors may be sensitive to inhibitors that perturb mitochondrial metabolism. When comparing the metabolic phenotype of tumor xenografts derived from parental or IDH1-mutant cells with our in vitro results, similar changes were detected, including increased glutamine anaplerosis and a decreased aKG to citrate ratio. The increase in glutamine anaplerosis we observe in the IDH1-mutant cells is in agreement with previous findings, which suggest that IDH1-mutant cells display an increased sensitivity to glutaminase inhibitors (25) . The similar metabolic changes that could be reliably measured in vivo suggest that the altered sensitivity we observe to inhibitors of mitochondrial metabolism in vitro may also be true in vivo. Additional studies are required to determine if cellular proliferation in the tumor microenvironment alone can drive hypoxia and induce reductive glutamine metabolism. Regardless, tumors would still be expected to increase their reliance on WT IDH1 (or cytosolic TCA) activity when treated with phenformin or other inhibitors of mitochondrial metabolism, suggesting that these strategies could be efficacious in IDH1-mutant cancers. As such, this increased susceptibility of cultured IDH1-mutant cells relative to parental cells or IDH2-mutant cells provides intriguing evidence of a potential therapeutic strategy associated with IDH1 mutational status and warrants further investigation in preclinical models.
We find that inhibition of mutant IDH1 is unable to reverse the observed metabolic phenotype. The DNA hypermethylator phenotype, which is highly associated with IDH mutation, is also not entirely reverted by a mutant IDH1 inhibitor (22) , providing further evidence that some, but not all, mutant IDHdependent phenotypes may be reversed by inhibitors targeting 2-HG production. Mechanistically, this result also suggests that the metabolic defect we observe may be independent of 2-HG production. A previous study used biochemical assays to quantify the effects of IDH1 mutations on reductive carboxylation activity, and, in agreement with our findings here, demonstrated that the mutant enzymes are unable to catalyze the conversion of aKG and CO 2 to isocitrate (26) . This study concluded that the subunits in a WT/mutant heterodimer function independently; however, our modeling data indicate that heterozygous IDH1 mutations lead to a much greater than 50% inhibition of reductive glutamine metabolism (Fig. 1F) , suggesting a possible dominant effect of the mutant protein in cells or alternatively global metabolic reprogramming in response to the compromised cytosolic IDH1 activity caused by these mutations.
Importantly, as small molecules capable of inhibiting mutant IDH1 enzymatic activity and preventing D-2-HG accumulation fail to rescue mutant cell metabolism under hypoxia, this suggests that combinatorial therapeutic strategies that block oncogenic D-2-HG production (e.g., via a mutant-selective inhibitor of enzyme function), while simultaneously targeting mutant IDH1-induced metabolic liabilities, may be a viable option for therapy. Such an approach could involve IDH1-mutant inhibitor treatment to attenuate any prosurvival or dedifferentiation effects of D-2-HG, while increasing the tumor's reliance on WT IDH1 activity through an inhibitor of oxidative mitochondrial metabolism. As drugs that could target the mutant IDH1 metabolic phenotype are already in the clinic (metformin, phenformin) and inhibitors of mutant IDH1 are currently being developed (22, 46) , it is hoped that this hypothesis will be tested in the clinic in the near future.
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